CoChat
Sign Up
Cited by 2,157Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

Open access
Taube, Janis M., Anders, Robert A., Young, Geoffrey D., Xu, Haiying, Sharma, Rajni, McMiller, Tracee L., Chen, Shuming, Klein, Alison P. +3 more·2012·Science Translational Medicine
DOI 10.1126/scitranslmed.3003689PMC PMC3568523
Open this paper in CoChat — free account

Abstract

Activated tumor-infiltrating lymphocytes may induce B7-H1 on melanocytes, which suggests adaptive resistance to antitumor immunity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3003689

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Both PD-L1 expression and TMB fail to encapsulate various tumor microenvironmental features influencing ICI responses.

    “However, both PDL-1 expression and TMB fail to encapsulate various tumor microenvironmental features influencing ICI responses15–17.”

    From Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images (2024) · cites this paper as [16]

    The Discussion (page unavailable) says clinical outcomes may depend on PD-L1 (B7-H1) expression alongside immune-infiltrate composition and persistent inflammation, and links an inflamed tumor microenvironment to immunotherapy response. This supports the point that PD-L1 expression alone does not capture all relevant features. The paper does not address tumor mutational burden or establish that TMB fails to capture features influencing checkpoint-inhibitor responses. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 46

  1. [1]Benlalam H Labarrière N Linard B Derré L Diez E Pandolfino MC Bonneville M Jotereau F Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): Implications for immunotherapy Eur. J. Immunol 2001 31 2007 2015 11449353
  2. [2]Kamposioras K Pentheroudakis G Pectasides D Pavlidis N Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature Crit. Rev. Oncol. Hematol 2011 78 112 126 20570171
  3. [3]Zou W Chen L Inhibitory B7-family molecules in the tumour microenvironment Nat. Rev. Immunol 2008 8 467 477 18500231
  4. [4]Ishida Y Agata Y Shibahara K Honjo T Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death EMBO J 1992 11 3887 3895 1396582 PMC556898
  5. [6]Dong H Zhu G Tamada K Chen L B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat. Med 1999 5 1365 1369 10581077
  6. [7]Freeman GJ Long AJ Iwai Y Bourque K Chernova T Nishimura H Fitz LJ Malenkovich N Okazaki T Byrne MC Horton HF Fouser L Carter L Ling V Bowman MR Carreno BM Collins M Wood CR Honjo T Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J. Exp. Med 2000 192 1027 1034 11015443 PMC2193311
  7. [8]Iwai Y Ishida M Tanaka Y Okazaki T Honjo T Minato N Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proc. Natl. Acad. Sci. U.S.A 2002 99 12293 12297 12218188 PMC129438
  8. [9]Topalian ST Weiner GJ Pardoll DM Cancer immunotherapy comes of age J. Clin. Oncol 2011 29 4828 4836 22042955 PMC3255990
  9. [10]Hodi FS O’Day SJ McDermott DF Weber RW Sosman JA Haanen JB Gonzales R Robert C Schadendorf D Hassel JC Akerly W van den Eertwegh AJ Lutzky J Lorigan P Vaubel JM Linette GP Hogg D Ottensmeier CH Lebbé C Peschel C Quirt I Clark JI Wolchok JD Weber JS Tian J Yellin MJ Nichol GM Hoos A Urba WJ Improved survival with ipilimumab in patients with metastatic melanoma N. Engl. J. Med 2010 363 711 723 20525992 PMC3549297
  10. [12]Downey SG Klapper JA Smith FO Yang JC Sherry RM Royal RE Kammula US Hughes MS Allen TE Levy CL Yellin M Nichol G White DE Steinberg SM Rosenberg SA Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade Clin. Cancer Res 2007 13 6681 6688 17982122 PMC2147083
  11. [13]Beck KE Blansfield JA Tran KQ Feldman AL Hughes MS Royal RE Kammula US Topalian SL Sherry RM Kleiner D Quezado M Lowy I Yellin M Rosenberg SA Yang JC Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte–associated antigen 4 J. Clin. Oncol 2006 24 2283 2289 16710025 PMC2140223
  12. [15]Brown JA Dorfman DM Ma FR Sullivan EL Munoz O Wood CR Greenfield EA Freeman GJ Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production J. Immunol 2003 170 1257 1266 12538684
  13. [16]Liang SC Latchman YE Buhlmann JE Tomczak MF Horwitz BH Freeman GJ Sharpe AH Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses Eur. J. Immunol 2003 33 2706 2716 14515254
  14. [17]Yamazaki T Akiba H Iwai H Expression of programmed death 1 ligands by murine T cells and APC J. Immunol 2002 169 5538 5545 12421930
  15. [19]Butte MJ Keir ME Phamduy TB Sharpe AH Freeman GJ Programmed death-1 ligand-interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses Immunity 2007 27 111 122 17629517 PMC2707944
  16. [20]Tivol EA Borriello F Schweitzer AN Lynch WP Bluestone JA Sharpe AH Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 Immunity 1995 3 541 547 7584144
  17. [21]Dong H Zhu G Tamada K Flies DB van Deursen JM Chen L B7-H1 determines accumulation and deletion of intrahepatic CD8+ T lymphocytes Immunity 2004 20 327 336 15030776
  18. [22]Nishimura H Okazaki T Tanaka Y Nakatani K Hara M Matsumori A Sasayama S Mizoguchi A Hiai H Minato N Honjo T Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice Science 2011 291 319 322 11209085
  19. [23]Flies DB Chen L The new B7s: Playing a pivotal role in tumor immunity J. Immunother 2007 30 251 260 17414316
  20. [24]Wu C Zhu Y Jiang J Zhao J Zhang XG Xu N Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance Acta Histochem 2006 108 19 24 16530813
  21. [26]Thompson RH Kuntz SM Leibovich BC Dong H Lohse CM Webster WS Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up Cancer Res 2006 66 3381 3385 16585157
  22. [27]Thompson RH Gillett MD Cheville JC Lohse CM Dong H Webster WS Krejci KG Lobo JR Sengupta S Chen L Zincke H Blute ML Strome SE Leibovich BC Kwon ED Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target Proc. Natl. Acad. Sci. U.S.A 2004 101 17174 17179 15569934 PMC534606
  23. [28]Ghebeh H Mohammed S Al-Omair A Qattan A Lehe C Al-Qudaihi G Elkum N Alshabanah M Bin Amer S Tulbah A Ajarim D Al-Tweigeri T Dermime S The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors Neoplasia 2006 8 190 198 16611412 PMC1578520
  24. [29]Brahmer JR Drake CG Wollner I Powderly JD Picus J Sharfman WH Stankevich E Pons A Salay TM McMiller TL Gilson MM Wang C Selby M Taube JM Anders R Chen L Korman AJ Pardoll DM Lowy I Topalian SL Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates J. Clin. Oncol 2010 28 3167 3175 20516446 PMC4834717
  25. [30]Thompson RH Dong H Kwon ED Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy Clin. Cancer Res 2007 13 709s 715s 17255298
  26. [31]Schrieber RD Old LJ Smyth MJ Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion Science 2011 331 1565 1570 21436444
  27. [32]Dunn GP Bruce AT Ikeda H Old LJ Schreiber RD Cancer immunoediting: From immunosurveillance to tumor escape Nat. Immunol 2002 3 991 998 12407406
  28. [33]Parsa AT Waldron JS Panner A Crane CA Parney IF Barry JJ Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma Nat. Med 2007 13 84 88 17159987
  29. [34]Wölfle SJ Strebovsky J Bartz H Sähr A Arnold C Kaiser C Dalpke AH Heeg K PD-L1 expression on tolerogenic APCs is controlled by STAT-3 Eur. J. Immunol 2011 41 413 424 21268011
  30. [35]Kinter AL Godbout EJ McNally JP Sereti I Roby GA O’Shea MA Fauci AS The common γ-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands J. Immunol 2008 181 6738 6746 18981091
  31. [36]Karim R Jordanova ES Piersma SJ Kenter GG Chen L Boer JM Melief CJ van der Burg SH Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma Clin. Cancer Res 2009 15 6341 6347 19825956
  32. [37]Gajewski TF Louahed J Brichard VG Gene signature in melanoma associated with clinical activity: A potential clue to unlock cancer immunotherapy Cancer J 2010 16 399 403 20693853
  33. [38]Ji RR Chasalow SD Wang L Hamid O Schmidt H Cogswell J Alaparthy S Berman D Jure-Kunkel M Siemers NO Jackson JR Shahabi V An immune-active tumor microenvironment favors clinical response to ipilimumab Cancer Immunol. Immunother 2011 PMC11028506 22146893
  34. [40]Zhang L Conejo-Garcia JR Katsaros D Gimotty PA Massobrio M Regnani G Makrigiannakis A Gray H Schlienger K Liebman MN Rubin SC Coukos G Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N. Engl. J. Med 2003 348 203 213 12529460
  35. [41]Fukunaga A Miyamoto M Cho Y Murakami S Kawarada Y Oshikiri T Kato K Kurokawa T Suzuoki M Nakakubo Y Hiraoka K Itoh T Morikawa T Okushiba S Kondo S Katoh H CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma Pancreas 2004 28 e26 e31 14707745
  36. [42]Eerola AK Soini Y Pääkkö P A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma Clin. Cancer Res 2000 6 1875 1881 10815910
  37. [43]Schumacher K Haensch W Röefzaad C Schlag PM Prognostic significance of activated CD8+ T cell infiltrations within esophageal carcinomas Cancer Res 2001 61 3932 3936 11358808
  38. [45]Webster WS Lohse CM Thompson RH Dong H Frigola X Dicks DL Sengupta S Frank I Leibovich BC Blute ML Cheville JC Kwon ED Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival Cancer 2006 107 46 53 16708355
  39. [46]Galon J Costes A Sanchez-Cabo F Kirilovsky A Mlecnik B Lagorce-Pagès C Tosolini M Camus M Berger A Wind P Zinzindohoué F Bruneval P Cugnenc PH Trajanoski Z Fridman WH Pagès F Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 2006 313 1960 1964 17008531
  40. [47]Clemente CG Mihm MC Jr Bufalino R Zurrida S Collini P Cascinelli N Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma Cancer 1996 77 1303 1310 8608507
  41. [48]Mihm MC Jr Clemente CG Cascinelli N Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response Lab. Invest 1996 74 43 47 8569196
  42. [49]Hino R Kabashima K Kato Y Yagi H Nakamura M Honjo T Okazaki T Tokura Y Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma Cancer 2010 116 1757 1766 20143437
  43. [50]Gadiot J Hooijkaas AI Kaiser ADM van Tinteren H van Boven H Blank C Overall survival and PD-L1 expression in metastasized malignant melanoma Cancer 2011 117 2192 2201 21523733
  44. [51]Curtin JA Fridlyand J Kageshita T Patel HN Busam KJ Kutzner H Cho KH Aiba S Bröcker EB LeBoit PE Pinkel D Bastian BC Distinct sets of genetic alterations in melanoma N. Engl. J. Med 2005 353 2135 2147 16291983
  45. [52]Curtin JA Busam K Pinkel D Bastian BC Somatic activation of KIT in distinct subtypes of melanoma J. Clin. Oncol 2006 24 4340 4346 16908931
  46. [53]Balch CM Gershenwald JE Soong SJ Thompson JF Atkins MB Byrd DR Buzaid AC Cochran AJ Coit DG Ding S Eggermont AM Flaherty KT Gimotty PA Kirkwood JM McMasters KM Mihm MC Jr Morton DL Ross MI Sober AJ Sondak VK Final version of 2009 AJCC melanoma staging and classification J. Clin. Oncol 2009 27 6199 6206 19917835 PMC2793035

Cited by

Sorted by citations

Authors
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., & Chen, L.
Affiliations
  • Johns Hopkins University (US)
  • Johns Hopkins Medicine (US)
Corresponding author
  • Taube, Janis M.
  • Topalian, Suzanne L.
  • Chen, Lieping
ORCID
Venue
Science Translational Medicine
Publisher
American Association for the Advancement of Science (AAAS)
Published
2012-03-28
Volume
4
Issue
127
Pages
127ra37-127ra37
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
DOI
10.1126/scitranslmed.3003689
PMC
PMC3568523
OpenAlex
W2057893793
Cited by
2,157
References
6
Citations by year
2026: 62 · 2025: 61 · 2024: 75 · 2023: 139 · 2022: 110 · 2021: 168 · 2020: 208 · 2019: 191 · 2018: 236 · 2017: 271 · 2016: 234 · 2015: 186 · 2014: 111 · 2013: 78 · 2012: 27
FWCI
63.63
Type
journal article
Language
en
Open access
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Cancer Institute (CA-85721, CA 97085, R01CA163594, R01CA097085, R01CA085721, CA-016359, R01CA142779, P30CA006973, P30CA016359)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK081417, R01DK080736)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
PD-L1, PD-1 pathway, tumor-infiltrating lymphocytes, melanoma, melanocytic nevi, immune evasion, interferon-gamma, tumor inflammation, adaptive immune resistance, immune checkpoint blockade
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Child, Demography, Female, Follow-Up Studies, Humans, Inflammation, Interferon-gamma, Male, Melanocytes, Melanoma, Middle Aged, Neoplasm Staging, Skin Neoplasms, Gene Expression Regulation, Neoplastic, Survival Analysis, Lymphocytes, Tumor-Infiltrating, Tumor Escape, Reverse Transcriptase Polymerase Chain Reaction, Young Adult, Adaptive Immunity, B7-H1 Antigen, Laser Capture Microdissection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review